WuXi Biologics (Cayman) Inc.
WuXi Biologics (Cayman) Inc. (WXXWY) Financial Performance & Income Statement Overview
Analyze WuXi Biologics (Cayman) Inc. (WXXWY) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
WuXi Biologics (Cayman) Inc. (WXXWY) Income Statement & Financial Overview
Explore comprehensive income reports for WuXi Biologics (Cayman) Inc. WXXWY, broken down by year and quarter.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $10.10B | $8.57B | $8.54B | $8.49B |
| Cost of Revenue | $5.80B | $5.22B | $5.27B | $4.93B |
| Gross Profit | $4.30B | $3.35B | $3.27B | $3.56B |
| Gross Profit Ratio | $0.43 | $0.39 | $0.38 | $0.42 |
| R&D Expenses | $422.38M | $344.06M | $451.14M | $341.44M |
| SG&A Expenses | $960.90M | $1.19B | $1.17B | $915.69M |
| Operating Expenses | $1.15B | $1.53B | $1.62B | $1.03B |
| Total Costs & Expenses | $6.95B | $6.75B | $6.90B | $5.96B |
| Interest Income | $350.37M | $0.00 | $64.67M | $3.98M |
| Interest Expense | $157.59M | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $783.73M | $653.32M | $636.14M | $359.31M |
| EBITDA | $3.96B | $2.47B | $2.27B | $2.66B |
| EBITDA Ratio | $0.39 | $0.29 | $0.27 | $0.31 |
| Operating Income | $3.15B | $1.82B | $1.65B | $2.30B |
| Operating Income Ratio | $0.31 | $0.21 | $0.19 | $0.27 |
| Other Income/Expenses (Net) | -$328.11M | $188.70M | -$1.14M | $226.61M |
| Income Before Tax | $2.83B | $2.008B | $1.64B | $2.53B |
| Income Before Tax Ratio | $0.28 | $0.23 | $0.19 | $0.30 |
| Income Tax Expense | $660.96M | $228.07M | $412.06M | $191.12M |
| Net Income | $1.86B | $1.50B | $1.13B | $2.27B |
| Net Income Ratio | $0.18 | $0.17 | $0.13 | $0.27 |
| EPS | $0.54 | $0.35 | $0.25 | $0.52 |
| Diluted EPS | $0.50 | $0.35 | $0.26 | $0.52 |
| Weighted Avg Shares Outstanding | $4.08B | $4.26B | $4.49B | $4.36B |
| Weighted Avg Shares Outstanding (Diluted) | $4.23B | $4.26B | $4.35B | $4.35B |
Over the past four quarters, WuXi Biologics (Cayman) Inc. demonstrated steady revenue growth, increasing from $8.49B in Q2 2023 to $10.10B in Q4 2024. Operating income reached $3.15B in Q4 2024, maintaining a consistent 31% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $3.96B, reflecting operational efficiency. Net income rose to $1.86B, with EPS at $0.54. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan